Core Insights - AEON Biopharma announced positive initial comparative analytical results for ABP-450, confirming identical amino-acid sequencing and highly similar functional characteristics to BOTOX [1][3] - The company reported constructive feedback from the FDA following a BPD Type 2a meeting, providing a clear framework for advancing the comparative analytical plan for the ABP-450 biosimilar program [1][2] - AEON strengthened its balance sheet through a $6 million PIPE financing and a note exchange, reducing outstanding debt by more than 90% [1][3] Financial Performance - As of December 31, 2025, AEON reported cash and cash equivalents of $3.0 million, which does not include $4.2 million from the second closing of the PIPE financing in January 2026 [5] - The company incurred a net loss of $39.2 million for the year ended December 31, 2025, compared to a net income of $42.0 million in 2024 [17] Corporate Developments - John Bencich was appointed as Chief Financial Officer, bringing over 25 years of leadership experience in corporate strategy and capital markets [4][10] - AEON plans to request a BPD Type 2b meeting in 2026 to discuss the next phase of the development program for ABP-450 [3] Market Context - The U.S. therapeutic neurotoxin market exceeds $3.0 billion annually, representing a significant opportunity for biosimilar entry [7] - ABP-450 is manufactured by Daewoong Pharmaceutical in a facility authorized by the FDA, Health Canada, and the European Medicines Agency [7]

Core Insights - The FDA provided constructive feedback on AEON Biopharma's analytical similarity strategy for ABP-450, a biosimilar to BOTOX, indicating support for the company's development approach [1][2][4] - AEON plans to request a BPD Type 2b meeting with the FDA in 2026 to discuss the next steps in the development program for ABP-450 [3] Company Overview - AEON Biopharma is focused on gaining full-label access to the U.S. therapeutic neurotoxin market, which exceeds $3.0 billion annually, through the development of ABP-450 [6] - ABP-450 is the same botulinum toxin complex currently marketed for cosmetic use as Jeuveau by Evolus, Inc. [6] - The product is already approved as a biosimilar in India, Mexico, and the Philippines, and AEON holds exclusive rights for therapeutic indications in the U.S., Canada, EU, UK, and other territories [6] Development Strategy - The FDA acknowledged the scientific challenges in characterizing the botulinum neurotoxin complex and provided feedback that supports AEON's analytical methodologies [2] - AEON aims to complete the majority of its analytical comparability program in 2026, which is crucial for advancing toward regulatory approval [2][4] - The analytical similarity is a critical phase in the biosimilar development process, potentially allowing the FDA to reduce the scope of required clinical studies if robust comparability is demonstrated [5]

Core Insights - Evolus is experiencing signs of stabilization in the U.S. botulinum toxin market, while the recovery for dermal fillers is slower due to changing consumer sentiment [6][5] - The company has raised its long-term revenue targets for 2028, anticipating $450 million to $500 million, with adjusted EBITDA margins of 13% to 15% [15] Market Trends - The filler market is recovering slower than toxins, with negative sentiment around "overfilled" faces impacting hyaluronic acid (HA) fillers [2] - The company expects the market for toxins to return to mid-single-digit growth by 2027 and 2028, aligning with low-single-digit growth assumptions currently [3][5] Consumer Behavior - The 2024 downturn in the market is attributed to middle-class consumers reducing discretionary spending amid economic uncertainty, affecting all age groups and practice settings [4] - Consumers are stretching intervals between treatments to maximize the value of their spending [4] Product Launch and Technology - Evolus' new product, Evolysse, is gaining traction, currently available in about 3,000 U.S. clinics, and is expected to be a top HA launch despite broader category declines [8][12] - The technology behind Evolysse involves manufacturing HA gel at near-freezing temperatures to preserve its natural structure, leading to positive feedback from practitioners [8][9] Training and Adoption - The company has conducted hands-on training for over 12,000 injectors, with a second training session noted as a key factor in increasing product utilization [10] Strategic Initiatives - Evolus is bundling its products, Jeuveau and Evolysse, to enhance market share and compete more effectively against larger competitors [11][12] - The company has a consumer loyalty program with over 1.4 million participants, designed to encourage repeat visits to clinics [15] International Market Presence - Evolus has a direct presence in several European countries and Australia, with an estimated $2 billion opportunity in international markets for toxins and fillers [16] - The company expects international revenue to grow from 8% to about 15% of total revenue by 2028 [18]

Summary of Evolus Conference Call Company Overview - **Company**: Evolus - **Industry**: Aesthetic medicine, specifically focusing on toxins and fillers Key Points Market Dynamics - The toxin market is showing signs of recovery after a challenging period, with improvements noted in Q4 of the previous year and continuing into Q1 of the current year [4][8] - Historically, the toxin market has only experienced three significant downturns: the 2008-2009 recession, COVID-19 shutdowns, and the recent slowdown attributed to middle-class consumers reducing spending due to rising costs [4][5] - The current guidance suggests low single-digit growth for the toxin market, with expectations of mid-single-digit growth by 2027-2028 [9] Consumer Behavior - The slowdown in the toxin market was primarily driven by middle-class consumers stretching intervals between treatments, seeking to maximize their spending [5][7] - Consumer confidence is beginning to improve, leading to increased clinic activity and a slight uptick in the Consumer Confidence Index [7][8] Filler Market Insights - The filler market is recovering at a slower pace compared to the toxin market, impacted by negative perceptions around overfilled faces [14][17] - Clinics are shifting their messaging to promote hyaluronic acid (HA) as a natural ingredient rather than a filler, which is expected to improve consumer sentiment [16][17] Product Differentiation - Evolus's filler product, Evolysse, is performing well despite a challenging market, with clinics appreciating its efficiency and natural look [37][39] - The company has trained over 12,000 injectors to enhance confidence in using Evolysse, which is crucial for its adoption [39] Financial Guidance - For 2026, Evolus projects revenues between $327 million and $337 million, representing a 10%-13% year-over-year growth [80] - By 2028, the revenue is expected to reach between $450 million and $500 million, with adjusted EBITDA margins of 13%-15% [82] - International revenue is anticipated to grow from 8% in 2025 to 15% by 2028, driven by expanding market presence in Europe and new product launches [83][118] Strategic Initiatives - Evolus is focusing on bundling its products to enhance market share and customer loyalty, with a pilot program showing positive results [40][41] - The company is also investing in co-branded media to support clinics, maintaining an annual advertising spend of $9 million to $12 million [170] Customer Loyalty Program - Evolus has developed a consumer loyalty program with over 1.4 million active participants, which incentivizes repeat visits to clinics [164][200] - The program is designed to be frictionless and automated, enhancing customer engagement and clinic partnerships [208][210] Future Outlook - The upcoming launch of the Sculpt product is expected to be a significant revenue driver, potentially accounting for 40% of the filler line's revenue [102][106] - Evolus aims to continue expanding its product portfolio and market presence, with a focus on both U.S. and international markets [121][122] Additional Insights - The international market for toxins and fillers represents a $2 billion opportunity, with Evolus currently holding a low single-digit market share [134][140] - The company is actively monitoring market trends and consumer behavior to adapt its strategies accordingly [152][153]

Core Insights - AEON Biopharma has appointed John Bencich as Chief Financial Officer to advance its lead asset ABP-450 through critical regulatory milestones [1][2] - The company aims to achieve accelerated and full-label U.S. market entry for ABP-450, a biosimilar to BOTOX, in a therapeutic market exceeding $3.0 billion annually [4] Company Developments - John Bencich brings over 25 years of experience in corporate strategy, capital market transactions, and business development, having previously served as CEO of Achieve Life Sciences [2] - His leadership is expected to enhance AEON's financial strategy, deepen institutional engagement, and support disciplined capital formation [2] - ABP-450 is manufactured by Daewoong Pharmaceutical and is already approved as a biosimilar in India, Mexico, and the Philippines [4] Regulatory Context - The FDA's 351(k) biosimilar pathway requires developers to demonstrate that a proposed product is highly similar to an approved reference biologic, with no clinically meaningful differences in safety, purity, or potency [3] - AEON's strategy involves a totality-of-evidence assessment that integrates analytical similarity with clinical and regulatory strategy [3]

Core Insights - AEON Biopharma is advancing ABP-450 as a biosimilar to BOTOX, aiming for accelerated and full-label U.S. market entry [1] - The company will present data at the 2026 American Academy of Neurology Annual Meeting, highlighting the analytical similarity of ABP-450 to the reference product [2][3] Company Overview - AEON Biopharma focuses on the U.S. therapeutic neurotoxin market, which exceeds $3.0 billion annually, presenting significant opportunities for biosimilar competition [5] - ABP-450 is manufactured by Daewoong Pharmaceutical under cGMP and is already approved as a biosimilar in India, Mexico, and the Philippines [5] - The company holds exclusive development and distribution rights for ABP-450 in the U.S., Canada, the EU, the UK, and other territories [5] Presentation Details - The poster presentation titled "Establishing Primary Structure Comparability Between ABP-450 and OnabotulinumtoxinA (Botox) to Support Biosimilarity" will take place on April 22, 2026 [4] - The session will be presented by Chad K. Oh, M.D., Chief Medical Officer of AEON Biopharma [4]

Core Insights - The company achieved a 12% full-year revenue growth despite a decline in U.S. injectable volumes for only the third time in 25 years [1] - Jeuveau captured a 14% market share through a 'beauty-first' strategy that focuses on cash-pay aesthetic practices rather than reimbursement models [1] - The company successfully piloted a new portfolio growth rebate program to incentivize accounts to consolidate toxin and filler spending with Evolus [1] Financial Performance - International revenue nearly doubled year-over-year, driven by a transition to a direct model in Germany and approaching double-digit market share in the U.K. [1] - A structural expense reset was executed in mid-2025 to align the organization for durable, profitable growth and meaningful operating leverage [1] Product and Market Strategy - The Evolysse HA filler footprint expanded to over 3,000 purchasing accounts, utilizing Cold-X Technology to meet consumer demand for natural-looking results [1] - The company maintained brand resilience through Evolus Rewards, an SMS-based loyalty program that has grown to over 1.4 million treated patients [1]

Financial Data and Key Metrics Changes - Global net revenue for Q4 2025 was $90.3 million, representing a 14% growth over Q4 2024, including $83.1 million from Jeuveau and $7.2 million from Evolysse [14][15] - For the full year 2025, global net revenue was $297.2 million, up 12% compared to 2024, marking the sixth consecutive year of double-digit growth [15][11] - Reported gross margin for Q4 was approximately 66%, with adjusted gross margin at approximately 67% [16] - GAAP operating expenses for Q4 were $55.1 million, down from $57.3 million in Q3, while non-GAAP operating expenses were $53 million, compared to $49.7 million in Q3 [17][18] - Non-GAAP operating income for Q4 was $7.1 million, compared to $6.7 million in Q4 2024 [19] Business Line Data and Key Metrics Changes - Jeuveau captured over 14% U.S. market share, continuing to gain share even in a declining procedural environment [9] - Evolysse, introduced in 2025, has over 3,000 customers, expanding the company's presence within accounts [10] - International revenue nearly doubled year-over-year, now representing approximately 8% of total revenue, with strong growth in markets like the U.K. [15][10] Market Data and Key Metrics Changes - The U.S. injectable procedural volumes declined for only the third time in 25 years, yet Evolus achieved 12% revenue growth in 2025 [11] - The neurotoxin market declined mid to upper single digits in 2025, but Jeuveau gained units despite new competition [56] - The filler market is expected to see low single-digit growth, with signs of recovery anticipated [56][88] Company Strategy and Development Direction - Evolus aims to build a global performance beauty company centered on differentiated brands for cash pay consumers, with a focus on expanding its product portfolio [12][26] - The company plans to introduce Estyme in Europe in Q2 2026 and expects FDA approval of Evolysse Sculpt in Q4 2026 [12][26] - Evolus is committed to driving profitable growth, targeting revenue between $450 million to $500 million by 2028 [12] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving sustained profitability beginning in 2026, with a low to mid-single-digit adjusted EBITDA margin expected [12][25] - The company noted that the aesthetic market is showing signs of recovery, particularly in the filler market, with expectations for gradual improvement [56][88] - Management highlighted the importance of customer loyalty programs and the positive feedback received from clinicians regarding product differentiation [32][56] Other Important Information - Evolus has entered into a revolving credit facility providing up to $30 million for working capital needs [21] - The company is not planning to raise equity capital and remains sensitive to dilution [22] Q&A Session Summary Question: Has the growth of Evolus been primarily from early adopters? - Management noted that the customer base is diversifying, with over 3,000 purchasing accounts contributing to revenue growth [30] Question: Can Evolus turn around market growth impacted by macro trends? - Management believes that while macro factors affect the market, there are signs of improvement in the filler market [34] Question: Can you provide details on the rebate program structure? - The rebate program is designed to reward clinics for increased purchases, with eligibility based on quarterly purchase volumes [42][43] Question: How is the overall marketing strategy described for 2026? - The marketing strategy includes digital advertising and co-promotions with beauty brands, tailored to individual clinics [46][47] Question: What are the assumptions regarding competitive launches in guidance? - Management acknowledged the expected launch of new competitors in 2026 but remains confident in their product differentiation and market position [62][80]

Financial Data and Key Metrics Changes - Global net revenue for Q4 2025 was $90.3 million, representing a 14% increase compared to Q4 2024, with Jeuveau revenue at $83.1 million and Evolysse at $7.2 million [14] - For the full year 2025, global net revenue reached $297.2 million, up 12% from 2024, marking the sixth consecutive year of double-digit growth [15] - Reported gross margin for Q4 was approximately 66%, with adjusted gross margin at about 67% [16] - GAAP operating expenses for Q4 were $55.1 million, down from $57.3 million in Q3, while non-GAAP operating expenses were $53 million, compared to $49.7 million in Q3 [17][18] - Cash at the end of Q4 was $53.8 million, up from $43.5 million at the end of Q3, driven by strong sales growth and disciplined expense management [19] Business Line Data and Key Metrics Changes - Jeuveau continues to capture over 14% of the U.S. market share, with sustained growth despite a declining procedural environment [9] - Evolysse, launched in 2025, has seen over 3,000 customers purchase the product, expanding the company's presence and share of injectable spend [10] - The company successfully piloted a new portfolio growth rebate program aimed at rewarding practices for increasing their business with Evolus [7] Market Data and Key Metrics Changes - International revenue nearly doubled year-over-year, now representing approximately 8% of total revenue, with strong growth in markets like the U.K. approaching double-digit market share [15][10] - The U.S. injectable procedural volumes declined for only the third time in 25 years, yet Evolus achieved a 12% revenue growth in 2025 [11] Company Strategy and Development Direction - Evolus aims to build a global performance beauty company focused on differentiated brands for cash-paying consumers, with plans to introduce Estyme in Europe and expect FDA approval for Evolysse Sculpt in Q4 2026 [12][26] - The company emphasizes education and training for clinicians, having provided hands-on training to over 14,000 clinicians in 2025 [8] Management's Comments on Operating Environment and Future Outlook - Management noted that the aesthetic market is showing signs of recovery, with expectations for low single-digit growth in the toxin market and gradual recovery in the filler market [55][89] - The company is optimistic about achieving profitability in 2026, with a target revenue between $450 million and $500 million by 2028 [12][25] Other Important Information - Evolus has entered into a revolving credit facility providing up to $30 million for working capital needs, supporting inventory build and preparation for product launches [21][22] - The company plans to transition its primary profitability metric to adjusted EBITDA starting in 2026 to improve comparability with industry peers [24] Q&A Session Summary Question: Has the growth of Evolus been primarily from early adopters or is it starting to broaden? - Management indicated that Evolus is diversifying its customer base, with over 3,000 purchasing accounts and positive feedback on the portfolio rebate program [31] Question: Can Evolus turn around market growth impacted by macro trends? - Management believes that while macro factors affect the market, there are signs of improvement in the filler market, with clinicians adapting to new trends [35] Question: Can you provide details on the rebate program structure? - The rebate program is designed to reward clinics based on purchasing volume, with positive feedback received during the pilot phase [44] Question: How is the toxin market trending based on internal data? - Management noted that the neurotoxin market declined mid to upper single digits in 2025, but there are signs of recovery, especially in the latter half of the year [55] Question: What are the assumptions regarding competitive launches in guidance? - Management acknowledged upcoming competitive launches but emphasized the importance of maintaining focus on their differentiated clinical data and customer satisfaction [62]

Financial Data and Key Metrics Changes - Global net revenue for Q4 2025 was $90.3 million, representing a 14% increase compared to Q4 2024, with Jeuveau revenue at $83.1 million and Evolysse at $7.2 million [13] - For the full year 2025, global net revenue reached $297.2 million, up 12% from 2024, marking the sixth consecutive year of double-digit growth [14] - Reported gross margin for Q4 was approximately 66%, with adjusted gross margin at about 67% [16] - GAAP operating expenses for Q4 were $55.1 million, down from $57.3 million in Q3, while non-GAAP operating expenses were $53 million, compared to $49.7 million in Q3 [17][18] Business Line Data and Key Metrics Changes - Jeuveau continues to capture over 14% of the U.S. market share, with sustained growth despite a declining procedural environment [8] - Evolysse, introduced in 2025, has seen over 3,000 customers purchase the product, expanding the company's presence and increasing overall share of injectable spend [9] - The Evolus Rewards program has grown to over 1.4 million treated patients, contributing to sustained share expansion [5] Market Data and Key Metrics Changes - International revenue nearly doubled year-over-year, now representing approximately 8% of global revenues, up from 5% in 2024 [14] - In key markets like the U.K., the company is approaching double-digit market share, reflecting strong positioning outside the U.S. [9] Company Strategy and Development Direction - The company aims to build a global performance beauty company centered on differentiated brands for cash pay consumers, with plans to introduce Estyme in Europe and expect FDA approval of Evolysse Sculpt [11][12] - The strategy includes a focus on education and training for clinicians, with over 14,000 clinicians trained in 2025 [6] Management's Comments on Operating Environment and Future Outlook - Management noted that 2025 was a unique year for the aesthetics market, with only the third decline in U.S. injectable procedural volumes in 25 years, yet the company achieved 12% revenue growth [10] - The outlook for 2026 includes expected revenue between $327 million and $337 million, representing 10% to 13% growth over 2025 results [22] Other Important Information - The company has entered into a revolving credit facility providing up to $30 million, which will be used for working capital needs [20] - The company does not plan to raise equity capital and remains sensitive to dilution [21] Q&A Session Summary Question: Has the growth of Evolus been primarily from early adopters? - Management indicated that the customer base is diversifying, with over 3,000 purchasing accounts contributing to Jeuveau revenue, and plans to broaden the customer base through sampling and training programs [28][29] Question: Can you provide details on the rebate program structure? - The rebate program is designed as a growth rebate for accounts purchasing over $50,000 or $100,000 in a quarter, aimed at encouraging clinics to commit more business to Evolus [42][43] Question: How is the overall marketing strategy structured for 2026? - The marketing strategy includes digital advertising, billboards, and co-promotions with beauty brands, all customized for clinics [46][48] Question: What are the assumptions regarding competitive launches in guidance? - Management expects new entrants in 2026 to create pressure but believes that established brands will maintain their market share through quality and customer satisfaction [60][61] Question: How is the seasonality trend for Q1? - The toxin market is showing solid demand, while the filler market remains pressured but not experiencing the same declines as in 2025 [86]